Patrick Wood
Stock Analyst at Morgan Stanley
(2.97)
# 1,304
Out of 4,814 analysts
81
Total ratings
39.29%
Success rate
1.7%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TFX Teleflex | Maintains: Overweight | $275 → $191 | $129.55 | +47.43% | 4 | Mar 5, 2025 | |
| SOLV Solventum | Maintains: Equal-Weight | $73 → $80 | $65.70 | +21.77% | 4 | Mar 5, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Equal-Weight | $45 → $22 | $16.86 | +30.53% | 4 | Mar 5, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $105 → $95 | $53.04 | +79.11% | 2 | Feb 26, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $75 → $82 | $68.61 | +19.52% | 7 | Feb 14, 2025 | |
| EW Edwards Lifesciences | Maintains: Equal-Weight | $70 → $75 | $71.56 | +4.81% | 8 | Feb 12, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $100 → $120 | $95.25 | +25.98% | 5 | Feb 6, 2025 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $104 → $102 | $79.55 | +28.22% | 5 | Dec 6, 2024 | |
| GKOS Glaukos | Downgrades: Underweight | $120 | $90.07 | +33.23% | 3 | Dec 2, 2024 | |
| BLCO Bausch + Lomb | Downgrades: Equal-Weight | $19 | $12.07 | +57.42% | 6 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $246.95 | +28.37% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $5.44 | +83.82% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $145 | $88.24 | +64.32% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $92.47 | -8.08% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $16.91 | +118.81% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $39 → $30 | $28.89 | +3.84% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $86 | $62.37 | +37.89% | 5 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $220.02 | -2.28% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $310 → $280 | $200.40 | +39.72% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $14.44 | +149.31% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $140.00 | - | 5 | Dec 11, 2017 |
Teleflex
Mar 5, 2025
Maintains: Overweight
Price Target: $275 → $191
Current: $129.55
Upside: +47.43%
Solventum
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $73 → $80
Current: $65.70
Upside: +21.77%
Tandem Diabetes Care
Mar 5, 2025
Downgrades: Equal-Weight
Price Target: $45 → $22
Current: $16.86
Upside: +30.53%
PROCEPT BioRobotics
Feb 26, 2025
Maintains: Overweight
Price Target: $105 → $95
Current: $53.04
Upside: +79.11%
DexCom
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $75 → $82
Current: $68.61
Upside: +19.52%
Edwards Lifesciences
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $70 → $75
Current: $71.56
Upside: +4.81%
Boston Scientific
Feb 6, 2025
Maintains: Overweight
Price Target: $100 → $120
Current: $95.25
Upside: +25.98%
The Cooper Companies
Dec 6, 2024
Maintains: Equal-Weight
Price Target: $104 → $102
Current: $79.55
Upside: +28.22%
Glaukos
Dec 2, 2024
Downgrades: Underweight
Price Target: $120
Current: $90.07
Upside: +33.23%
Bausch + Lomb
Dec 2, 2024
Downgrades: Equal-Weight
Price Target: $19
Current: $12.07
Upside: +57.42%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $246.95
Upside: +28.37%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $5.44
Upside: +83.82%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $88.24
Upside: +64.32%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $92.47
Upside: -8.08%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $16.91
Upside: +118.81%
Jul 15, 2024
Downgrades: Underweight
Price Target: $39 → $30
Current: $28.89
Upside: +3.84%
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $74 → $86
Current: $62.37
Upside: +37.89%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $220.02
Upside: -2.28%
Dec 4, 2023
Maintains: Overweight
Price Target: $310 → $280
Current: $200.40
Upside: +39.72%
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $14.44
Upside: +149.31%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $140.00
Upside: -